SAN FRANCISCO, CA — August 18, 2025 — Leads & Copy — FibroGen, Inc. (NASDAQ: FGEN) announced that the China State Administration for Market Regulation has approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited, according to the Share Purchase Agreement dated February 20, 2025.
The closing of the transaction is still subject to certain contractual closing conditions and deliverables. The company anticipates the deal will close in the third quarter of 2025.
FibroGen, Inc. is a biopharmaceutical company focused on developing novel therapies for cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is approved in China, Europe, Japan, and other countries for treating anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The company is evaluating a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (FOR46), an antibody-drug conjugate (ADC) targeting CD46, is in development for metastatic castration-resistant prostate cancer. This program includes FG-3180, a CD46-targeted PET biomarker.
David DeLucia, CFA, Senior Vice President and Chief Financial Officer, can be reached at ir@fibrogen.com.
Source: FibroGen
